Repositioning Candidate Details

Candidate ID: R0750
Source ID: DB05236
Source Type: investigational
Compound Type: biotech
Compound Name: ReN001
Synonyms: --
Molecular Formula: --
SMILES: --
DrugBank Description: ReN001 is a clonal human neural stem cell line developed for clinical use in the treatment of stable disability after stroke. ReN001 a strong candidate for one of the first cell-based IND applications to be submitted to the Food and Drug Administration in the United States for consideration for the treatment of stroke in humans.
CAS Number: --
Molecular Weight:
DrugBank Indication: For the treatment of stroke.
DrugBank Pharmacology: ReN001 is a clonal human neural stem cell line which has been conditionally immortalized using the fusion transgene c-mycERTAM to allow controlled expansion when cultured in the presence of 4-hydroxytamoxifen. The cell line has been banked and fully characterized to assure there is genetic stability and no phenotypic drift with extended passages. In vivo studies determined the ability of the cell line to survive after implantation into damaged brain and its efficacy in the reduction of chronic behavioural dysfunction after implantation into a rodent model of stroke damage. A further study was conducted in this model and a dose-dependent effect was observed on behavioural recovery. No safety or toxicology issues were identified in in vivo studies with this cell line.
DrugBank MoA: --
Targets: --
Inclusion Criteria: Indication associated